BioCentury

8:00 AM GMT, Feb 26, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Ebb & Flow Focus

Actelion Ltd. (SWX:ATLN) shed $615 million in market value last week, despite reporting that 2006 EPS jumped 85%, as investors apparently have some concerns about what’s ahead for the company.

Revenues and EPS have been driven by Tracleer bosentan for pulmonary arterial hypertension. But as Tracleer growth slows, the company’s earnings growth is doing the same, even without potential upcoming competition

Read the full 619 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.